Keymed Biosciences Inc. (HKG:2162)
Hong Kong
· Delayed Price · Currency is HKD 74.50
-0.75 (-1.00%)
Apr 29, 2026, 4:08 PM HKT
Keymed Biosciences Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Net Income | - | -515.24 | -359.36 | -308.12 | -3,887 | Upgrade
|
| Depreciation & Amortization | - | 91.84 | 68.78 | 35.79 | 20.94 | Upgrade
|
| Other Amortization | - | 1.39 | 0.39 | 0.34 | 0.08 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 1.08 | 0.07 | 0.39 | 0.71 | Upgrade
|
| Loss (Gain) on Equity Investments | - | 5.26 | 4.75 | 9.71 | 0.72 | Upgrade
|
| Stock-Based Compensation | - | 34.35 | 40.08 | 48.57 | 116.82 | Upgrade
|
| Other Operating Activities | - | -81.49 | -78.62 | -182.94 | 3,531 | Upgrade
|
| Change in Accounts Receivable | - | -35.76 | -27.09 | 3.98 | -3.98 | Upgrade
|
| Change in Inventory | - | -55.07 | -11.86 | -28.1 | -9.55 | Upgrade
|
| Change in Accounts Payable | - | -3.48 | 14.58 | 12.13 | -0.63 | Upgrade
|
| Change in Unearned Revenue | - | -0.45 | -0.81 | - | -7 | Upgrade
|
| Change in Income Taxes | - | -6.19 | -1.32 | - | - | Upgrade
|
| Change in Other Net Operating Assets | - | -34.04 | 46.8 | 6.32 | 23.99 | Upgrade
|
| Operating Cash Flow | - | -789.63 | -303.62 | -401.93 | -214.64 | Upgrade
|
| Capital Expenditures | - | -207.91 | -378.49 | -278.82 | -171.79 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -6.58 | -4.12 | -0.73 | -1.07 | Upgrade
|
| Investment in Securities | - | 162.4 | 700.46 | -575.02 | -1,870 | Upgrade
|
| Other Investing Activities | - | 119.8 | 150.35 | 208.98 | 6.95 | Upgrade
|
| Investing Cash Flow | - | 67.71 | 468.2 | -645.59 | -2,036 | Upgrade
|
| Long-Term Debt Issued | - | 468.79 | 360 | 89.95 | - | Upgrade
|
| Total Debt Issued | - | 468.79 | 360 | 89.95 | - | Upgrade
|
| Short-Term Debt Repaid | - | - | -0.23 | -0.33 | -41.82 | Upgrade
|
| Long-Term Debt Repaid | - | -135.55 | -93.66 | -14.52 | -12.91 | Upgrade
|
| Total Debt Repaid | - | -135.55 | -93.88 | -14.85 | -54.73 | Upgrade
|
| Net Debt Issued (Repaid) | - | 333.24 | 266.12 | 75.1 | -54.73 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 2,888 | Upgrade
|
| Repurchase of Common Stock | - | -32.43 | -32.9 | -51.14 | - | Upgrade
|
| Other Financing Activities | - | -16.91 | -161.09 | -32.03 | -8.5 | Upgrade
|
| Financing Cash Flow | - | 283.9 | 72.13 | -8.06 | 3,638 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 5.41 | 10.25 | 139.03 | -66.65 | Upgrade
|
| Net Cash Flow | - | -432.62 | 246.96 | -916.55 | 1,321 | Upgrade
|
| Free Cash Flow | - | -997.55 | -682.11 | -680.76 | -386.42 | Upgrade
|
| Free Cash Flow Margin | - | -233.00% | -192.63% | -680.33% | -350.44% | Upgrade
|
| Free Cash Flow Per Share | - | -3.81 | -2.61 | -2.61 | -2.40 | Upgrade
|
| Cash Interest Paid | - | 18.15 | 10.49 | 1.85 | - | Upgrade
|
| Levered Free Cash Flow | - | -565.77 | -714.05 | -410.26 | -231.71 | Upgrade
|
| Unlevered Free Cash Flow | - | -554.23 | -703.27 | -405.01 | -224.75 | Upgrade
|
| Change in Working Capital | - | -326.82 | 20.29 | -5.67 | 2.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.